Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Mar;29(3):294-301.
doi: 10.1016/j.jiac.2022.12.004. Epub 2022 Dec 15.

Validation of a specialized evaluation system for COVID-19 in Japan: A retrospective, multicenter cohort study

Affiliations
Multicenter Study

Validation of a specialized evaluation system for COVID-19 in Japan: A retrospective, multicenter cohort study

Hiroki Furuhata et al. J Infect Chemother. 2023 Mar.

Abstract

Introduction: Evaluation of a severity grade (SG) is important to classify patients for efficient use of limited medical resources. This study validates two existing evaluation systems for the prevention of the coronavirus disease 2019 (COVID-19) in Japan: a criterion of SG and a list of 14 specialized underlying diseases (SUDs).

Methods: A retrospective cohort was created using electronic medical records from 18 research institutes. The cohort includes 6,050 COVID-19 patients with two types of diagnosis information as follows: SG at hospitalization among mild, moderate I, moderate II, and severe and aggravation after hospitalization.

Results: A crude mortality rate and an aggravation rate increased by the worsening of SG in the COVID-19 cohort. The transition of the aggravation rate was notable for COVID-19 patients with SUD. A conditional probability of the mortality given the aggravation in the COVID-19 cohort was 87.4% compared to mild or moderate patients (approximately 21%-45%) who have the possibility of the aggravation. An odds ratio of the mortality and aggravation information about the SUD list was higher than other variables.

Conclusions: We demonstrated the possibility of improving the criteria of SG by including the SUD list for more effective operation of the criteria of SG. Furthermore, we demonstrated the importance of the prevention of the aggravation based on the conditional probability, and the possibility of predicting the aggravation using the risk factors.

Keywords: COVID-19; Infection; Severity; Underlying disease.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest HF has no competing interests. KA received a research fund as the director of the Japan Medical Network Association from the Kyoto University.

Figures

Fig. 1
Fig. 1
Data processing flowchart.

References

    1. Marin B.G., Aghagoli G., Lavine K., Yang L., Siff E.J., Chiang S.S., et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2020;31:e2146. doi: 10.1002/rmv.2146. - DOI - PMC - PubMed
    1. Del Valle D.M.D., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–1643. doi: 10.1038/s41591-020-1051-9. - DOI - PMC - PubMed
    1. Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microb Infect. 2020;9:1123–1130. doi: 10.1080/22221751.2020.1770129. - DOI - PMC - PubMed
    1. Shibata S., Arima H., Asayama K., Hoshide S., Ichihara A., Ishimitsu T., et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese society of hypertension task force on COVID-19. Hypertens Res. 2020;43:1028–1046. doi: 10.1038/s41440-020-0515-0. - DOI - PMC - PubMed
    1. Robilotti E.V., Babady N.E., Mead P.A., Rolling T., Perez-Johnston R., Bernardes M., et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–1223. doi: 10.1038/s41591-020-0979-0. - DOI - PMC - PubMed

Publication types